Miraculins Makes Unsolicited Bid to Acquire Dx Shop IBEX

Nov 17, 2006

NEW YORK (GenomeWeb News) — Biomarker research company Miraculins today said it has made an unsolicited offer to acquire Montreal-based IBEX, a cancer and arthritis diagnostics company.

"The cancer diagnostic programs of Miraculins and IBEX are extremely complementary, and future opportunities for our companies are enhanced by this transaction", Miraculins President Jim Charlton said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Skipped Steps

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

Just a Few Bats

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

This Week in Nature

In Nature this week: investigation into the genetics of medulloblastoma, and more.

Genomics for the Trees

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.

Main menu